MPI Research

Jim Laveglia, Ph.D., has been named executive vice president at MPI Research. Tina Rogers, PhD, MBA, DABT, has been named to Dr. Laveglia’s former role of director of research.

In his new role, Dr. Laveglia will focus on business development and will continue to serve on the company’s corporate management team and board of directors. Dr. Laveglia joined MPI soon after its inception in the mid-1990’s, and became director of research in February 1997. Prior to MPI, he served as director of toxicology and animal metabolism at Ricerca, Inc. In his numerous leadership positions in the chemical industry and with contract toxicology laboratories, he has directed the activities of toxicologists, pathologists, technical staff, report-preparation staff, and overall corporate operations.

Tina Rogers, PhD, MBA, DABT joined MPI in 2007 as director of the Discovery Center and associate director of research. In her new role as director of research and member of the Corporate Management Team, she will continue to lead major growth initiatives for the company. With more than 20 years of experience in the CRO industry, she has held key leadership positions, most recently as vice president of drug development at Southern Research Institute.

Bill Parfet, MPI’s chairman and chief executive officer, remarked, “These are exciting but challenging economic times for the pharmaceutical and biotech customers that we serve. The contract research organizations that partner with them in moving their drug and device candidates forward need to demonstrate sharper business acumen and greater scientific expertise than ever before and Drs. Laveglia and Rogers bring those attributes to the table.”